Clinical Trials Arena April 9, 2024
Prothea plans to use the funds to start clinical trial for cancer imaging, biopsy and laser ablation treatment in lung cancer patients.
The University of Edinburgh and Bath spin-off, Prothea Technologies, has closed €12m ($13m) in Series A financing to develop cancer diagnostics and therapeutics.
The company aims to develop cancer management technologies to address two challenges – inaccurate biopsies and limited interventional treatment options for small lesions.
The Series A financiers include European venture capital companies Earlybird Venture Capital and Mérieux Equity Partners, along with the University of Edinburgh’s venture investment firm Old College Capital, and NRW.BANK, the promotional bank of North Rhine-Westphalia (NRW).
Prothea plans to use the funds to advance its cancer medical device, which consists of...
Today's Sponsors
Today's Sponsor